生物科技公司CureVac B.V.（股票代码：CVAC）今日盘中股价大涨34.15%，引发市场高度关注。这一显著涨幅主要源于一则重大收购消息。
据报道，德国生物科技巨头BioNTech已同意以约12.5亿美元的全股票交易收购CureVac。根据交易条款，CureVac的投资者每持有1股CureVac股票，将获得约5.46股BioNTech股票。这一收购价格较CureVac昨日收盘价溢价约34%，这解释了为什么CureVac股价在盘中出现如此大幅度的上涨。
这笔交易对双方都具有重要战略意义。对BioNTech而言，收购CureVac将有助于其增强在癌症治疗领域的业务实力。BioNTech首席执行官Ugur Sahin表示，此次收购将整合"互补的资源"，以增强公司在癌症治疗方面的能力。对CureVac来说，被行业巨头收购不仅能为公司带来可观的溢价，还可能为其研发项目提供更多资源和支持。值得注意的是，此次交易也为德国政府（目前持有CureVac 13.3%的股权）提供了一个退出机会，预计德国政府将获得约1.63亿美元的BioNTech股票。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.